New EMA Research on ServiceOps Quantifies the Impact of AI, Automation, and Modular Integration across Industries

Survey of 204 IT leaders reveals that ServiceOps has evolved into a unified operational approach combining IT service, ITOps, and ESM with AI, automation, observability, and cross-team collaboration to align IT delivery with business value Enterprise Management Associates (EMA™), a leading IT research and consulting firm, has released a new report, “Redefining Modern Service Management: […]

Grand Opening of bonap: Alexis Nihon’s New Food Court

Grand Opening of bonap: Alexis Nihon's New Food Court GlobeNewswire November 25, 2025 MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) — bonap, Alexis Nihon's new food court, is now open! The community can gather in the redesigned space to enjoy tasty moments in a fresh, inviting setting. “The creation of this new food court represents a

Immorta Bio Announces Publication of International Patent Application for SenoVax™, a First-in-Class Senolytic Immunotherapy

Targeting the Root Causes of Aging Demonstrates Powerful Anti-Cancer Activity Across Multiple Tumor Models Immorta Bio Inc., a scientific longevity company pioneering therapies focusing on Treating Diseases of Aging and Treating Aging as Disease™, today announced the publication of its international patent application PCT/WO2025184665[1], entitled “Senescence Vaccine.” The application describes Immorta Bio's proprietary approach to

Teva receives European Commission approvals for PONLIMSI(R) (denosumab) Biosimilar to Prolia(R) and DEGEVMA(R) (denosumab) Biosimilar to Xgeva(R)

(NYSE:TEVA),(TASE:TEVA.TA),(TASE:TEVA), Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva's biosimilars PONLIMSI and DEGEVMA expanding access to important bone health treatments across Europe These approvals mark another significant milestone in Teva's strong biosimilars portfolio, in line with Teva's Pivot to Growth

Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System

(NASDAQ:NNOX), Althea France, part of one of Europe's largest independent medical technology services providers, to distribute CE-marked Nanox.ARC system across French healthcare sector Partnership represents Nanox's fourth European distribution agreement following recent collaborations in Greece, Romania and Czech Republic PETACH TIKVA, ISRAEL – November 25, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the

CLASS ACTION NOTICE: Berger Montague Advises James Hardie Industries PLC (NYSE: JHX) Investors to Inquire About a Securities Fraud Class Action

National plaintiffs' law firm Berger Montague PCannounces a class action lawsuit against James Hardie Industries plc (NYSE: JHX) (“James Hardie” or the “Company”) on behalf of investors who purchased James Hardie common stock and American Depositary Shares during the period ofMay 20, 2025 through August 18, 2025 (the “Class Period”). https://mma.prnewswire.com/media/232479/berger_montague.jpg Investor Deadline: Investors who

Gloo Acquires XRI Global, Unlocking Advanced Multilingual and Voice AI Capabilities to Expand Market Opportunity

Strategic acquisition will accelerate growth by embedding advanced multilingual AI across the Gloo platform Gloo (Nasdaq: GLOO), a technology platform serving the faith and flourishing ecosystem, announced it has acquired XRI Global, an AI company pioneering voice AI and multilingual technologies designed to engage people across thousands of languages. https://mma.prnewswire.com/media/2831576/XRI_Press_Release__1.jpg XRI's capabilities allow Gloo to

Teva receives European Commission approvals for PONLIMSI(R) (denosumab) Biosimilar to Prolia(R) and DEGEVMA(R) (denosumab) Biosimilar to Xgeva(R)

Teva receives European Commission approvals for PONLIMSI(R) (denosumab) Biosimilar to Prolia(R) and DEGEVMA(R) (denosumab) Biosimilar to Xgeva(R) GlobeNewswire November 25, 2025 Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva's biosimilars PONLIMSI and DEGEVMA expanding access to important bone health treatments

Scroll to Top